BCHE and early-onset autosomal dominant Alzheimer disease: One systematic review found no clinically important differences between groups receiving cholinesterase inhibitors and those receiving a placebo in the development of behavioral and neuropsychiatric symptoms of Alzheimer’s disease [11].